A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and Ozempic, the company announced Thursday. The once-daily pill, called

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat obesity and diabetes.

Shares of Eli Lilly jumped 12% in premarket trading Thursday after the pharmaceutical company released Phase 3 trial results for its oral weight-loss drug that "demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines.